{
    "2021-01-26": [
        [
            {
                "time": "2021-01-05",
                "original_text": "FIDELITY INVESTMENT TRUST减持泰格医药(03347)17.4万股，每股作价约179.26港元 减持股份",
                "features": {
                    "keywords": [
                        "FIDELITY INVESTMENT TRUST",
                        "减持",
                        "泰格医药",
                        "17.4万股",
                        "179.26港元"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-30",
                "original_text": "医疗健康行业基金4Q分析：四季度医药板块配置环比下降 机构持仓进一步集中",
                "features": {
                    "keywords": [
                        "医疗健康",
                        "基金",
                        "4Q",
                        "医药板块",
                        "配置下降",
                        "机构持仓集中"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-01-08",
                "original_text": "瑞银：上调泰格医药(03347)目标价79.9%至268港元 评级“买入”",
                "features": {
                    "keywords": [
                        "瑞银",
                        "上调",
                        "泰格医药",
                        "目标价",
                        "268港元",
                        "买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-10",
                "original_text": "高瓴资本概念股市值普遍调整，恩捷股份、凯莱英、公牛集团、甘李药业、泰格医药均大跌",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "概念股市值调整",
                        "恩捷股份",
                        "凯莱英",
                        "公牛集团",
                        "甘李药业",
                        "泰格医药",
                        "大跌"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-25",
                "original_text": "医药行业Q42020持仓分析：医药仓位有所回落 核心资产持续加强",
                "features": {
                    "keywords": [
                        "医药行业",
                        "Q42020",
                        "持仓分析",
                        "医药仓位回落",
                        "核心资产加强"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-01-12",
                "original_text": "大行评级|瑞银：上调泰格医药(3347.HK)目标价至268港元评级“买入”",
                "features": {
                    "keywords": [
                        "大行评级",
                        "瑞银",
                        "上调",
                        "泰格医药",
                        "目标价",
                        "268港元",
                        "买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-15",
                "original_text": "A股午盘综述：上证指数跌1.2%，创业板指跌2.39%",
                "features": {
                    "keywords": [
                        "A股",
                        "午盘综述",
                        "上证指数",
                        "跌1.2%",
                        "创业板指",
                        "跌2.39%"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "整体市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-01-18",
                "original_text": "【行情】港股生物医药板块集体下挫，泰格医药跌5.9%，康希诺生物跌5.2%，药明康德跌5.1%，药明生物跌4.8%，百济神州跌4% 连续下跌",
                "features": {
                    "keywords": [
                        "港股",
                        "生物医药板块",
                        "集体下挫",
                        "泰格医药",
                        "康希诺生物",
                        "药明康德",
                        "药明生物",
                        "百济神州",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-01-20",
                "original_text": "【权益变动】泰格医药(03347-HK)被FIDELITY INVESTMENT TRUST减持17.4万股 减持股份",
                "features": {
                    "keywords": [
                        "权益变动",
                        "泰格医药",
                        "FIDELITY INVESTMENT TRUST",
                        "减持",
                        "17.4万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-12-28",
                "original_text": "中信建投五大研究团队复盘2020年四季度公募基金持仓",
                "features": {
                    "keywords": [
                        "中信建投",
                        "研究团队",
                        "复盘",
                        "2020年四季度",
                        "公募基金持仓"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "整体市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-01-22",
                "original_text": "泰格医药(03347.HK)遭NINETEYONEUK减持12.18万股 减持股份",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "NINETEYONEUK",
                        "减持",
                        "12.18万股"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}